Moderna
MRNA
$45.72
-4.97%
Moderna, Inc. is a commercial-stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, operating within the dynamic healthcare sector. The company established itself as a dominant platform leader and disruptor through the rapid validation and global deployment of its COVID-19 vaccine, which propelled it from a clinical-stage entity to a commercial powerhouse. The current investor narrative is intensely focused on the company's transition beyond its pandemic windfall, debating its ability to successfully develop and commercialize a broad pipeline across infectious diseases, oncology, and rare genetic conditions, with recent news highlighting both promising early-stage vaccine data and significant legal settlements that impact its financials.…
MRNA
Moderna
$45.72
Related headlines
Investment Opinion: Should I buy MRNA Today?
Rating & Thesis: Moderna is rated a Hold. The core thesis is that while the validated mRNA platform and deep pipeline offer significant long-term optionality, the stock's premium valuation, severe cash burn, and lack of near-term earnings visibility create an unfavorable risk/reward profile at current levels, warranting caution despite the promising technology.
Supporting Evidence: The Hold rating is supported by four key data points. First, the valuation is rich at a PS of 5.90x, a premium to industry peers, despite a negative trailing PE of -4.07. Second, revenue growth is negative, with a 29.1% YoY decline in Q4. Third, profitability is deeply negative, with a net margin of -145.2% and operating margin of -158.1%. Fourth, analyst sentiment is neutral-to-cautious, with ratings like 'Equal Weight' and 'Sector Perform' reflecting the high uncertainty, as shown by the wide dispersion in revenue estimates ($5.71B to $10.12B).
Risks & Conditions: The two biggest risks to the thesis are an acceleration in cash burn threatening the balance sheet and further disappointing COVID-19 sales. This Hold rating would upgrade to a Buy if the PS multiple compresses below 4x (closer to industry average) on sustained pipeline progress, or if the company demonstrates a clear path to positive free cash flow. It would downgrade to a Sell if quarterly revenue falls below $500 million or if R&D fails to produce positive Phase 3 data for a major pipeline asset. Based on the current data, the stock appears fairly valued to slightly overvalued relative to its near-term fundamentals, but retains speculative value for its long-term platform potential.
Sign up to view all
MRNA 12-Month Price Forecast
The 12-month outlook for Moderna is highly binary, balanced between its promising platform and dire financials. The neutral stance reflects a 50% probability assigned to a base case of range-bound trading between $45 and $55, as the market awaits concrete pipeline commercialization. The confidence is medium due to the extreme dispersion in analyst revenue estimates, indicating high uncertainty. The stance would upgrade to bullish on evidence of sustained gross margin expansion above 60% or a definitive path to positive operating cash flow. It would downgrade to bearish if quarterly R&D spend fails to yield tangible pipeline milestones or if the cash balance declines precipitously without a corresponding revenue inflection.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Moderna's 12-month outlook, with a consensus price target around $59.44 and implied upside of +30.0% versus the current price.
Average Target
$59.44
8 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
8
covering this stock
Price Range
$37 - $59
Analyst target range
Analyst coverage is limited, with only 8 analysts providing estimates, indicating this is a stock with significant institutional debate and potentially higher volatility due to less efficient price discovery. The consensus sentiment appears neutral to cautious, as evidenced by recent institutional ratings which include actions like 'Equal Weight' from Morgan Stanley, 'Sector Perform' from RBC Capital, and 'Underperform' from B of A Securities, though a firm like Piper Sandler maintains an 'Overweight' rating. The target price range is not explicitly provided in the data, but the wide dispersion in revenue estimates—from a low of $5.71 billion to a high of $10.12 billion—signals very high uncertainty among analysts regarding the company's near-term commercial performance; this wide spread reflects divergent views on the timing of new product launches and the sustainability of COVID vaccine sales, making a single consensus target less meaningful.
Bulls vs Bears: MRNA Investment Factors
The investment debate for Moderna is a classic battle between transformative platform potential and harsh near-term financial reality. The bull case is anchored in the validated mRNA technology, a deep pipeline of 35 candidates, a strong balance sheet, and a valuation that has significantly compressed from historic highs. The bear case focuses on the unsustainable cash burn (-$2.05B TTM FCF), volatile and declining COVID-dependent revenue (-29.1% YoY in Q4), and a premium valuation (5.90x PS) despite deep losses. Currently, the bearish evidence holds stronger weight due to the concrete, present-tense financial deterioration and lack of near-term profitability. The single most important tension is the timing mismatch between massive ongoing R&D investment ($775M last quarter) and the commercialization of new products. The thesis hinges entirely on whether pipeline successes can materialize into profitable revenue streams before the company's substantial cash reserves are depleted.
Bullish
- Validated Platform with Broad Pipeline: Moderna's mRNA platform has been clinically validated by its COVID-19 vaccine, and the company is advancing a broad portfolio of 35 candidates across infectious diseases, oncology, and rare diseases. Positive early-stage data for its hantavirus vaccine, as highlighted in recent news, demonstrates the platform's versatility and potential for new revenue streams beyond COVID-19.
- Strong Technical Momentum and Recovery: The stock has gained 107.36% over the past year, breaking out from its 52-week low of $22.28 and currently trading near $49.04. This powerful uptrend, coupled with a 97.98% gain over the past six months, signals a major shift in market sentiment and a potential re-rating of the company's long-term prospects.
- Robust Balance Sheet with Low Debt: The company maintains a strong liquidity position with a current ratio of 3.29 and a low debt-to-equity ratio of 0.22. This financial fortress provides significant runway to fund its expansive R&D efforts, totaling $775 million last quarter, without the immediate pressure of dilutive financing.
- Attractive Valuation Relative to History: The stock's trailing Price-to-Sales (PS) ratio of 5.90x is near the lower end of its own historical spectrum, which has seen multiples above 100x. This suggests the market has de-risked the valuation from peak pandemic optimism, potentially offering a more reasonable entry point for the platform's long-term potential.
Bearish
- Severe and Sustained Cash Burn: The company is burning cash at an alarming rate, with trailing twelve-month Free Cash Flow deeply negative at -$2.054 billion and a Q4 2025 net loss of $826 million. With a net margin of -145.2%, the path to profitability is long and dependent on successful commercialization of pipeline assets, which is highly uncertain.
- Extreme Revenue Volatility and Decline: Revenue is highly volatile and declining, with Q4 2025 revenue of $678 million representing a 29.1% year-over-year contraction. While sequential quarters show lumpiness, this underscores the company's current dependence on unpredictable COVID-19 vaccine sales, which are in a structural decline.
- High Valuation Premium and Negative Profitability: Despite negative earnings, the stock trades at a PS ratio of 5.90x, a premium to the typical biotech industry range of 3x-5x sales. This premium valuation is difficult to justify given the lack of near-term profitability, a trailing PE of -4.07, and negative operating and net margins.
- Analyst Skepticism and High Uncertainty: Analyst sentiment is neutral to cautious, with ratings including 'Equal Weight', 'Sector Perform', and 'Underperform'. Furthermore, revenue estimates for the next period show extreme dispersion, ranging from $5.71B to $10.12B, indicating very high uncertainty and a lack of consensus on the commercial outlook.
MRNA Technical Analysis
The prevailing price trend is a powerful recovery and sustained uptrend, with the stock posting a remarkable 107.36% gain over the past year. Currently trading at $49.04, the price sits at approximately 82% of its 52-week range ($22.28 to $59.55), indicating it is closer to yearly highs, which reflects strong momentum but also suggests potential for overextension if bullish catalysts fail to materialize. Recent momentum shows a short-term divergence, with the stock down 9.62% over the past month, contrasting sharply with its positive 16.13% return over the last three months; this one-month weakness signals a potential consolidation or profit-taking phase following the explosive longer-term rally, especially as the Relative Strength over one month is a stark -15.22 versus the S&P 500. Key technical levels are clearly defined, with major support at the 52-week low of $22.28 and immediate resistance near the yearly high of $59.55; a decisive breakout above $59.55 would signal a resumption of the primary bull trend, while a breakdown below recent lows near $45 could indicate a deeper correction. The stock's beta of 1.056 indicates it is roughly 6% more volatile than the broader market, which is moderate for a biotech but still necessitates careful risk management given the sector's inherent binary event risks.
Beta
1.06
1.06x market volatility
Max Drawdown
-35.5%
Largest decline past year
52-Week Range
$22-$60
Price range past year
Annual Return
+73.2%
Cumulative gain past year
| Period | MRNA Return | S&P 500 |
|---|---|---|
| 1m | -14.9% | +3.3% |
| 3m | -1.9% | +6.9% |
| 6m | +104.5% | +12.4% |
| 1y | +73.2% | +23.4% |
| ytd | +48.2% | +7.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MRNA Fundamental Analysis
Revenue trajectory is highly volatile and currently declining, with Q4 2025 revenue of $678 million representing a 29.1% year-over-year contraction; however, examining sequential quarters shows revenue rebounding from a low of $107 million in Q1 2025 to $1.016 billion in Q3 2025 before the Q4 dip, indicating lumpy sales rather than a consistent downward trend, largely tied to the timing of COVID vaccine orders. The company is deeply unprofitable at the net income level, with a Q4 2025 net loss of $826 million and a trailing net margin of -145.2%, though the gross margin of 55.3% remains healthy; profitability is severely pressured by massive ongoing Research & Development investments, which totaled $775 million in the last quarter alone as Moderna funds its expansive clinical pipeline of 35 candidates. Balance sheet and cash flow health is a critical concern, with trailing twelve-month Free Cash Flow deeply negative at -$2.054 billion, yet the company maintains a strong liquidity position with a current ratio of 3.29 and a manageable debt-to-equity ratio of 0.22; the substantial cash burn highlights the company's dependence on its existing cash reserves to fund operations, making pipeline success and future product launches imperative to achieve sustainable positive cash flow.
Quarterly Revenue
$678000000.0B
2025-12
Revenue YoY Growth
-0.29%
YoY Comparison
Gross Margin
+0.33%
Latest Quarter
Free Cash Flow
$-2.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MRNA Overvalued?
Given Moderna's negative net income of -$826 million for the latest quarter, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The trailing PS ratio stands at 5.90x, while the forward-looking metric is not explicitly provided, though analyst revenue estimates for the next period average $6.83 billion, which would imply a forward PS based on the current market cap. The stock trades at a significant premium to typical biotechnology industry averages, which often range between 3x to 5x sales; a PS of 5.90x represents a premium, which the market is assigning based on the potential of its platform technology and pipeline beyond current COVID-related sales. Historically, Moderna's own PS ratio has fluctuated wildly, from recent highs above 100x during periods of minimal revenue to lows near 17x; the current 5.90x is near the lower end of its own historical spectrum, suggesting the market has significantly de-risked the valuation from peak pandemic optimism and may be pricing in a more conservative outlook for near-term growth.
PE
-4.1x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -13x~495x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-4.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Moderna faces severe financial risks stemming from its massive cash burn and lack of profitability. The company reported a Q4 2025 net loss of $826 million and a trailing net margin of -145.2%, with Free Cash Flow deeply negative at -$2.054 billion over the last twelve months. This unsustainable burn rate, driven by $775 million in quarterly R&D spending, creates a runway risk; the company must successfully commercialize new products before depleting its cash balance. Revenue is also highly concentrated and volatile, with Q4 sales down 29.1% YoY, highlighting dependence on a declining COVID-19 vaccine franchise and creating significant earnings unpredictability.
Market & Competitive Risks: The primary market risk is valuation compression. Trading at a PS ratio of 5.90x, Moderna commands a premium to the biotech industry average (3x-5x), yet lacks the earnings to support it. This premium is vulnerable to compression if pipeline readouts disappoint or if the broader market sours on high-growth, unprofitable biotech stocks. Competitive disruption is a constant threat, as evidenced by news of BioNTech's leadership pivoting to new mRNA ventures and Novavax reporting strong sales, indicating intense rivalry in the vaccine space. The stock's beta of 1.056 indicates it is slightly more volatile than the market, amplifying downside moves during sector-wide sell-offs.
Worst-Case Scenario: The worst-case scenario involves a combination of pipeline failures in key late-stage candidates, faster-than-expected erosion of COVID-19 revenue, and a sustained risk-off environment for biotech. This could trigger a severe de-rating, sending the stock back to its 52-week low of $22.28 as investors lose faith in the platform's commercial viability. Such a scenario would represent a downside of approximately -55% from the current price of $49.04. A sustained period of negative cash flow could also force dilutive equity raises, further pressuring the share price. The recent -9.62% one-month decline and -15.22% relative underperformance versus the market is a warning signal of this potential vulnerability.
FAQ
The key risks are, in order of severity: 1) Financial Sustainability Risk: The company is burning cash at an unsustainable rate, with -$2.05B in TTM Free Cash Flow, threatening its runway to fund R&D. 2) Commercialization Risk: Revenue is volatile and declining (-29.1% YoY in Q4), heavily reliant on COVID-19 sales with no near-term profitable replacement. 3) Pipeline Execution Risk: The valuation hinges on the success of 35 clinical candidates; failure in key late-stage trials could crater the stock. 4) Valuation Compression Risk: Trading at a premium PS ratio of 5.90x with negative earnings, the stock is vulnerable to multiple contraction if growth disappoints or interest rates rise.
The 12-month forecast for MRNA is highly uncertain, with a wide range of potential outcomes. Our analysis outlines three scenarios: a Bull Case (25% probability) with a target of $65-$75, driven by pipeline successes and valuation re-rating. A Base Case (50% probability) with a target of $45-$55, assuming continued volatility and range-bound trading as the company navigates declining COVID sales. A Bear Case (25% probability) with a target of $22-$30, triggered by pipeline failures and accelerated cash burn. The base case is most likely, centered on the analyst revenue consensus near $6.8 billion, but the extreme dispersion in estimates ($5.71B to $10.12B) underscores the high degree of forecast uncertainty.
Based on traditional metrics, MRNA appears overvalued. It trades at a Price-to-Sales (PS) ratio of 5.90x, which is a premium to the typical biotechnology industry range of 3x-5x, despite the company being deeply unprofitable with a trailing net margin of -145.2%. However, relative to its own history where PS ratios have exceeded 100x, the current multiple is at the lower end, suggesting the market has already priced out much of the pandemic-era optimism. The valuation implies the market is paying a premium for the optionality of the mRNA platform's future success, not for current fundamentals. This makes it a story stock where valuation is secondary to pipeline execution.
MRNA is a speculative buy only for investors with a high risk tolerance and a long-term investment horizon. The stock offers significant upside if its broad pipeline of 35 mRNA candidates succeeds, but this is counterbalanced by severe near-term financial challenges, including a -145.2% net margin and -$2.05 billion in trailing free cash flow. With a premium PS ratio of 5.90x and analyst sentiment leaning neutral-to-cautious, the current risk/reward is not compelling for most investors. It could become a good buy on a significant pullback towards the lower $30s, which would better compensate for the execution risk.
MRNA is unsuitable for short-term trading due to its high volatility (beta of 1.056), binary event risk from clinical data, and lack of earnings visibility. It is purely a long-term, speculative investment for investors willing to hold for 3-5 years or more to see if its mRNA pipeline can mature into commercial products. The company is in a capital-intensive development stage, with profitability likely years away, making it irrelevant for income investors (dividend yield is 0%). Given the need for multiple clinical and regulatory catalysts to play out, a minimum holding period of 18-24 months is suggested to weather the inherent volatility and assess pipeline progress.